Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review

Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review

<b>Objective:</b> Phase II/III randomized clinical trials (RCTs) are vulnerable to many types of bias beyond randomization. Insights into the reporting quality of RCTs involving migraine patients treated with monoclonal antibodies targeting the calcitonin gene-related peptide system (ant...

Full description

Bibliographic Details
Main Authors: Dimitrios Rikos, Michail Vikelis, Emmanouil V. Dermitzakis, Panagiotis Soldatos, Dimitrios Rallis, Jobst Rudolf, Anna P. Andreou, Andreas A. Argyriou
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Journal of Clinical Medicine
Subjects:
migraine
prevention
calcitonin gene-related peptide (CGRP)
monoclonal antibody
quality
risk of bias
Online Access:https://www.mdpi.com/2077-0383/13/7/1964

Similar Items

Similar Items